

"Express Mail" mailing label number _____	
Date of Deposit _____	
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Printed Name _____	Signature _____

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant:	Konstantinos Gavardinas	Group Art Unit: 1714
Serial No.:	10/598,330	
International		Conf No.: 2716
Application Date:	February 18, 2005	
US Nat'l Entry		
Date:	August 24, 2006	
Title:	BICYCLIC SUBSTITUTED INDOLE-DERIVATIVE STEROID HORMONE NUCLEAR RECEPTOR MODULATORS	
Docket No.:	X-16125	

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of documents BA-BE and CA-CB for consideration by the Examiner.

Applicants would also like to address the references disclosed on pages 5-7 of the specification. These references were disclosed in the specification to provide general background concerning the state of the art relating to nuclear hormone receptor modulators and indole-derivative compounds. However, it is not believed that all of these references are material to the patentability of the present invention and, thus, all of the references appearing on pages 5-7 have not been listed on the accompanying form 1449. If so desired by Examiner, copies of all the references disclosed in the specification will be provided.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

/Alexander Wilson/

Alexander Wilson  
Attorney for Applicant(s)  
Registration No. 45,782  
Phone: 317-277-0190

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

September 5, 2007